British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority review of gepotidacin, an oral antibiotic to treat sexually transmitted uncomplicated gonorrhoea.

London: GSK plc has announced that a supplemental New Drug Application for gepotidacin has been accepted by the US Food and Drug Administration (FDA) for priority review as an oral option for

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review application for gepotidacin, an oral antibiotic aimed at treating sexually transmitted uncomplicated gonorrhoea.

Gepotidacin was approved by the FDA earlier this year, under the Blujepa brand, as the first oral antibiotic to offer a new mechanism of action in uncomplicated urinary tract infections (uUTIs) in nearly 30 years. That indication was also granted a priority review by the agency, and is also under review in the UK and Australia.

GSK plc's experimental antibiotic, gepotidacin, has been granted priority review by the U.S. Food and Drug Administration (FDA) for a new use.

GSK (NYSE:GSK) announced on Monday that the U.S. FDA has granted priority review for its marketing application, aimed at expanding the availability of its antibacterial agent gepotidacin for patients with gonorrhea,